证券代码：002773 证券简称：康弘药业 公告编号：2024-044 成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第六次会议和二〇二三年度股东大会审议通过了《关于使 用自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲 置自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性 存款），购买原则为安全性高、流动性好、由商业银行发行并提供保本 承诺的短期保本型理财产品（包括结构性存款），购买期限为自股东大 会审议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董 事会授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买 决策权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露 媒体和巨潮资讯网（www.cninfo.com.cn）刊登于2024年4月25日《第八 届董事会第六次会议决议公告》（公告编号：2024-010）及2024年5月17 日《二〇二三年度股东大会决议公告》（公告编 ...

会计机构负责 | | | 井资产负债表 24年6月30日 | | | --- | --- | --- | --- | | 编制单位:成都康引 | | | 单位:人民币元 | | 功 | 附注 | 2024年6月30日 | 2024年1月1日 | | 流动资产: | | | | | 货币资金 | S 1 | 2, 999, 322, 489. 68 | 4, 702, 142, 704. 60 | | 结算备付金 | | | | | 拆出资金 | | | | | 交易性金融资产 | 七、2 | 2, 120, 000, 000. 00 | | | 衍生金融资产 | | | | | 应收票据 | 七、3 | | | | 应收账款 | 七、4 | 217, 366, 726. 06 | 160, 406, 614. 48 | | 应收款项融资 | | | | | 预付款项 | 七、6 | 25,533,757.43 | 10, 482, 586. 49 | | 应收保费 | | | | | 应收分保账款 | | | | | 应收分保合同准备金 | | | | | 其他应收款 | 七、5 | 12, 184, 809 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥2,294,131,650.05, representing a 19.46% increase compared to ¥1,920,404,752.87 in the same period last year[11]. - Net profit attributable to shareholders of the listed company reached ¥692,220,039.94, up 31.77% from ¥525,339,192.02 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥678,370,200.35, reflecting a 33.10% increase from ¥509,652,451.63 in the previous year[11]. - The net cash flow from operating activities was ¥805,017,530.51, which is a 44.84% increase compared to ¥555,792,925.34 in the same period last year[11]. - Basic earnings per share increased to ¥0.75, up 31.58% from ¥0.57 in the previous year[11]. - Total assets at the end of the reporting period were ¥8,875,572,812.88, a 4.06% increase from ¥8,529,680,910.70 at the end of the previous year[11]. - Net assets attributable to shareholders of the listed company were ¥8,153,759,334.68, reflecting a 4.48% increase from ¥7,804,029,406.63 at the end of the previous year[11]. - The company achieved operating revenue of CNY 2,294,131,650.05, representing a year-on-year growth of 19.46%[25]. - Net profit attributable to shareholders reached CNY 69,222,000, marking a year-on-year increase of 31.77%[23]. - Research and development investment amounted to CNY 195,209,786.20, reflecting a 6.90% increase compared to the previous year[25]. Strategic Focus and Product Development - The main business focus remains on the R&D, manufacturing, and sales of pharmaceuticals and medical devices, with no significant changes in the first half of 2024[15]. - The company emphasizes innovation in biopharmaceutical technology and green synthesis of chemical raw materials as key competitive advantages[15]. - The product pipeline includes various medications for conditions such as diabetes, depression, and eye diseases, with several products covered by national health insurance[16][17]. - The company aims to enhance its market presence through continuous product innovation and strategic collaborations[15]. - The overall strategy focuses on high-quality and sustainable growth in the pharmaceutical industry[15]. - The company has developed a product portfolio focused on chronic diseases such as hypertension and diabetes, with a strong emphasis on innovative treatments for common diseases in respiratory and digestive fields[19]. - The company is advancing several key projects in clinical trials, including KH631 and KH658 for age-related macular degeneration, and KH110 for Alzheimer's disease, with KH110 currently in Phase III trials[20]. - The company has established a comprehensive R&D system, integrating various research institutes and focusing on key therapeutic areas such as ophthalmology, neurology, and oncology[19]. - The company is actively expanding its international presence, with multiple first-class new drugs and international patents, aiming to explore global markets[21]. - The company has two gene therapy projects approved for clinical trials in both China and the U.S., highlighting its innovation in biopharmaceuticals[21]. Financial Management and Investment - Investment income from financial products reached ¥19,373,394.19, indicating effective cash management strategies[14]. - The company reported a non-operating loss of ¥213,897.27 from the disposal of non-current assets[13]. - Government subsidies recognized in the current period amounted to ¥20,475,317.28, contributing positively to the financial results[13]. - The company incurred a loss of ¥969,600.00 related to cash-settled share-based payments[13]. - The company’s cash and cash equivalents decreased by 179.50% to CNY -1,720,992,926.66, primarily due to increased investments in financial products[25]. - The total amount of raised funds used in the reporting period was ¥756.77 million, with a cumulative usage of ¥210.58 million[31]. - The solid oral dosage form project has achieved an investment progress of 92.24% with a cumulative investment of ¥23,181.67 million[32]. Environmental Compliance and Sustainability - The company is classified as a key pollutant discharge unit and adheres to various environmental protection laws and standards[59]. - Chengdu Kanghong Pharmaceutical Group reported significant progress in environmental compliance with multiple projects receiving environmental impact assessments and completion approvals, including the solid oral dosage technology transformation project and the innovative biological new drug laboratory project[60][61][62]. - The company has implemented a comprehensive environmental emergency response plan, demonstrating its commitment to environmental safety and compliance[61]. - The company is committed to sustainable practices, as shown by its adherence to various environmental regulations and standards across its projects[60][61]. - The company has established a comprehensive environmental monitoring plan, including online monitoring systems for key pollutants such as COD and ammonia nitrogen[87]. - The company is focused on maintaining sustainable practices, as evidenced by the consistent compliance with environmental standards across all monitored parameters[74]. Corporate Governance and Social Responsibility - The company emphasizes compliance with laws and regulations to protect shareholder and creditor rights, ensuring value creation for shareholders[97]. - Chengdu Kanghong Pharmaceutical actively participates in social welfare and charity initiatives, promoting public health and positive energy in the pharmaceutical sector[96]. - The company has been recognized as a leading enterprise in social responsibility, receiving multiple awards in the first half of 2024[105]. - The company donated over 8.72 million yuan in social welfare contributions in the first half of 2024, with cumulative donations exceeding 614 million yuan[104]. - The company established 6 traditional Chinese medicine planting bases across four provinces, covering over 4,000 acres, providing employment for over 450 local farmers and generating over 2.4 million yuan in income for them[106]. Shareholder Information and Stock Options - The total number of shares increased from 919,463,954 to 919,756,504 due to the exercise of stock options, resulting in an increase of 292,550 shares[128]. - The largest shareholder, Chengdu Kanghong Technology Industry Group Co., Ltd., holds 31.75% of the shares, totaling 292,014,900 shares[131]. - The stock options exercise was approved by the board on August 25, 2023, and has been registered with the Shenzhen Securities Registration and Clearing Company[128]. - The company has not implemented any share buyback during the reporting period[129]. - The report indicates that the stock option exercise diluted the earnings per share and net asset value per share metrics[128]. Market Expansion and Future Outlook - The company plans to launch three new products in the next quarter, targeting a market expansion of 10% in the oncology segment[89]. - The company aims for a revenue growth target of 12% for the full year 2024, with a projected revenue of CNY 3.2 billion[89]. - Market expansion efforts include entering two new provinces, which are expected to contribute an additional CNY 100 million in revenue[89]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of CNY 500 million allocated for this purpose[89]. - Future guidance estimates a revenue growth of 18% for the full year 2024, driven by new product launches and market expansion[90].

2021 年股票期权激励计划首次授予部分第三个行权期及预 留授予部分第二个行权期可行权激励对象名单 根据成都康弘药业集团股份有限公司于 2024 年 8 月 22 日召开 第八届董事会第八次会议审议通过的《关于 2021 年股票期权激励计 划首次授予部分第三个行权期及预留授予部分第二个行权期行权条 件达成的议案》，2021 年股票期权激励计划首次授予部分第三个行权 期及预留授予部分第二个行权期可行权激励对象名单如下： 注：1）上表中本次可行权股票期权数量以中国证券登记结算有限责任公司深圳分公司 实际确认数为准； 2）若在激励对象行权前公司有资本公积转增股本、派送股票红利、股份拆细、配股、 分红派息或缩股等事项，应对股票期权数量进行相应的调整； 3）以上激励对象已剔除 33 名 2023 年度个人绩效考核未达标人员及 31 名离职人员。 成都康弘药业集团股份有限公司 | 序号 | 姓名 | 序号 | 姓名 | | --- | --- | --- | --- | | 80 | 贾真珍 | 204 | 周建清 | | 81 | 蒋勇 | 205 | 周侃 | | 82 | 康悦 | 206 | 周晓军 | | 83 ...

二〇二四年八月 | 一、本次注销、本次行权事项的批准与授权 6 | | --- | | 二、本激励计划注销部分股票期权的具体情况 8 | | 三、本激励计划首次授予部分股票期权第三个行权期和预留授予部分股票期 | | 权第二个行权期行权条件成就的具体情况 9 | | 四、本激励计划首次授予股票期权第三个行权期和预留授予股票期权第二个 | | 行权期行权的具体安排 11 | | 五、结论意见 12 | 释义 在本法律意见书中，除非文中另有说明，下列词语具有如下涵义： 北京市通商（深圳）律师事务所 关于 成都康弘药业集团股份有限公司 2021 年股票期权激励计划 注销部分股票期权 及首次授予部分股票期权第三个行权期、预留授予部分股 票期权第二个行权期行权条件成就的 法律意见书 中国深圳市南山区海德三道 168 号航天科技广场 A 座 23 层 518067 23/F, Building A, CASC Plaza, No. 168 Haide 3rd Road Nanshan District, Shenzhen 518067, China 电话 Tel: +86 755 8351 7570 传真 Fax: +8 ...

证券代码：002773 证券简称：康弘药业 公告编号：2024-040 成都康弘药业集团股份有限公司 关于2021年股票期权激励计划首次授予部分第三个行权期 及预留授予部分第二个行权期行权条件达成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2021 年股票期权激励计划符合首次授予部分第三个行 权期行权条件的 252 名激励对象在首次授予部分第三个行权期可行 权的股票期权数量共计 234.9150 万份，行权价格为 21.65 元/股；符 合预留授予部分第二个行权期行权条件的 2 名激励对象在预留授予 部分第二个行权期可行权的股票期权数量共计 3.60 万份，行权价格 为 14.44 元/股。 2、本次行权采用自主行权模式。根据公司《2021 年股票期权激 励计划（草案）》，本次 2021 年股票期权激励计划首次授予股票期 权第三个行权期为自首次授予日起 36 个月后的首个交易日起至首次 授予日起 48 个月内的最后一个交易日当日止，预留授予股票期权的 第二个行权期为自预留授予日起 24 个月后的首个交易日起至预留授 予日起 3 ...

1 2024年1-6月非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：成都康弘药业集团股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的会 | 2024年期初占用资金 | 2024年1-6月占用累 | 2024年1-6月占用资 | 2024年1-6月偿还累 | 2024年1-6月期末占 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 计科目 | 余额 | 计发生金额（不含利 息） | 金的利息 | 计发生金额 | 用资金余额 | 占用形成原因 | | | 控股股东、实际控制人及其附属企业 | 无 | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企业 | 无 | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他关联方及附属企业 | 无 | | | | | | | | | | | ...

证券代码：002773 证券简称：康弘药业 公告编号：2024-039 成都康弘药业集团股份有限公司 第八届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届监 事会第八次会议于 2024 年 8 月 22 日在公司会议室以现场和通讯相结 合的方式召开。会议通知于 2024 年 8 月 12 日以书面、传真或电子邮 件等形式向所有监事发出。本次监事会应到监事 3 名，实到监事 3 名 （其中：监事会主席龚文贤先生以通讯方式参加），会议由监事会主 席龚文贤主持，公司董事会秘书列席会议。本次会议的召开符合《中 华人民共和国公司法》和《成都康弘药业集团股份有限公司章程》的 有关规定。 二、监事会会议审议情况 会议以书面记名投票方式通过了如下决议： 1. 会议以3票同意，0票反对，0票弃权审议通过了《2024年半年 度报告及摘要》。 1 / 4 经审核，监事会认为：董事会编制和审核的公司《2024 年半年 度报告》及摘要的程序符合法律、行政法规和中国证监会的规定，报 ...

证券代码：002773 证券简称：康弘药业 公告编号：2024-038 一、董事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届董 事会第八次会议于2024年8月22日在公司会议室通过现场和通讯相结 合的方式召开。会议通知已于2024年8月12日以书面、传真或电子邮 件等形式向所有董事发出。本次董事会应到董事九名，实到董事九名 （其中：董事柯潇先生、王霖先生、张志荣先生，独立董事周德敏先 生、邓宏光先生以通讯方式参加），会议由董事长柯尊洪先生主持， 公司监事、董事会秘书及高级管理人员列席了会议。本次会议的召开 符合《中华人民共和国公司法》和《成都康弘药业集团股份有限公司 章程》的有关规定。 二、董事会会议审议情况 会议以书面记名投票方式表决通过了如下决议： 1. 会议以9票赞成、0票反对、0票弃权审议通过了《2024年半年 度报告及摘要》。 《2024 年半年度报告》于 2024 年 8 月 23 日披露在公司指定信 1 / 4 成都康弘药业集团股份有限公司 第八届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 ...